| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c0caff3bf0deb84e360d07cc5e12bbb3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_78587acbfc8d4c9e9ac3baa7021087d7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_abce2697843a07a6d83bfe754c3d0fec |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16632
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16643
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16621
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16671
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-01
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2810-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5256
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-572
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-585 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-763
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-245
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-763
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| filingDate |
2006-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bba8806c73efc45aa33a8e28efeabd2d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9aa2596a1d60fc7c4e1cdb102ee3833e |
| publicationDate |
2007-01-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2007002373-A2 |
| titleOfInvention |
Use of mutant herpes simplex virus-2 for cancer therapy |
| abstract |
The present invention is directed to the composition and use of a modified Herpes Simplex Virus Type 2 (HSV-2) as a medicament in the treatment of cancer. The modified HSV-2 has fusogenic activity, and comprises a modified/mutated ICP10 polynucleotide encoding a polypeptide having ribonucleotide reductase activity and lacking protein kinase activity. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2008237098-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2015246086-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021087019-A1 |
| priorityDate |
2005-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |